| Literature DB >> 15605675 |
Abstract
Lipid-lowering is established as proven intervention to reduce atherosclerosis and its complications. This article summarises novel developments in the lipid-altering therapies under development. It also discusses other therapeutic targets, such as squalene synthase, microsomal transfer protein, acyl-cholesterol acyl transferase, cholesterol ester transfer protein, peroxosimal proliferator-activating receptors and lipoprotein (a), for which compounds have been developed and have at least reached trials in animal models. Lipid-altering drugs are likely to prove a fast-developing area for novel treatments, as possible synergies exist between new and established compounds for the treatment of atherosclerosis.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15605675 DOI: 10.1111/j.1742-1241.2004.00087.x
Source DB: PubMed Journal: Int J Clin Pract ISSN: 1368-5031 Impact factor: 2.503